COVID-19: CLINICAL CHARACTERISTICS AND OUTCOMES DEPENDING ON COMORBID PATHOLOGY

Purpose is to evaluate the clinical characteristics and outcomes of the new COVID-19 coronavirus infection, taking into account concomitant pathology.Material and methods. A retrospective analysis of the case histories of 190 patients hospitalized during the period May - June2020 at the Moscow City Clinical Hospital № 4 was carried out.Results and discussion. The spectrum of clinical manifestations in patients was dominated by intoxication, dry cough, shortness of breath, sore throat. In the 75+ age group, mortality reached 25% and was significantly more common. When comparing groups of patients with moderate (n=119, 62,6%) and severe (n=71, 37,4%), a relationship was found between the severity of the condition and certain concomitant pathology: diseases of the cardiovascular system, chronic decompensated kidney pathology and cerebrovascular disease, which indicates that these belong to significant risk factors associated with with a severe course of the disease.Conclusions. Patients over the age of 75 years with concomitant cardiovascular diseases, chronic kidney diseases complicatedby renal insufficiency, as well as cerebrovascular disease, represent a risk group for severe COVID-19.

COVID-19, risk factors, comorbid diseases, cardiovascular diseases, chronic kidney diseases, cerebrovascular disease

1. Clinical characteristics of coronavirus disease 2019 in China / W.J. Guan [et al.] // N. Engl. J. Med. - 2020. - Vol. 382, № 18. - P. 1708-1720.

2. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis / W.J. Guan [et al.] // Eur. Respir. J. - 2020. - Vol. 55, № 5. - P. 2000547.

3. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy / G. Grasselli [et al.] // JAMA Intern. Med. - 2020. - Vol. 180, № 10. - P. 1345-1355.

4. Features of 20133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study / A.B. Docherty [et al.] // BMJ. - 2020. - Vol. 369. - P. m1985.

5. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives / M. Nishiga [et al.] // Nat. Rev. Cardiol. - 2020. - Vol. 17, № 9. - P. 543-558.

6. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China / D. Wang [et al.] // JAMA. - 2020. - Vol. 323, № 11. - P.1061-1069.

7. Gansevoort, R.T. CKD is a key risk factor for COVID-19 mortality / R.T. Gansevoort, L.B. Hilbrands // Nat. Rev. Nephrol. - 2020. - Vol. 16, № 12. - P. 705-706.

8. The impact of SARS-CoV-2 on the most common comorbidities - a retrospective study on 814 COVID-19 deaths in Romania / M.G. Barbu [et al.] // Front Med (Lausanne). - 2020. - Vol. 7. - P. 567199.

9. Comorbidity and its impact on patients with COVID-19 / A. Sanyaolu [et al.] // SN Compr. Clin. Med. - 2020. - Vol. 2, № 8. - P. 1069-1076.

10. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis / Y. Zhou [et al.] // Int. J. Infect. Dis. - 2020. - Vol. 99. - P. 47-56.

11. Acute respiratory distress syndrome: the Berlin definition / V.M. Ranieri [et al.] // JAMA. - 2012. - Vol. 307, № 23. - P. 2526-2533.